Deal or no deal?
No, this isn’t a reference to the once-popular TV game show. Instead, it’s the question that investors are asking about Gilead Sciences. The big biotech’s executives have publicly stated that acquisitions are a priority for this year. But 2017 is now more than halfway over -- and no deal is in sight.
Would an acquisition really help Gilead that much anyway? Look to the past to see what the future could hold. Here’s a look at the seven acquisitions made by Gilead Sciences over the last decade along with a grade for each deal.
